{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T18:10:12Z","timestamp":1790359812831,"version":"4.1.0"},"publisher-location":"Cham","reference-count":103,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783319914381","type":"print"},{"value":"9783319914398","type":"electronic"}],"license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018]]},"DOI":"10.1007\/978-3-319-91439-8_1","type":"book-chapter","created":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T20:25:48Z","timestamp":1533155148000},"page":"1-27","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":61,"title":["Imatinib Mesylate"],"prefix":"10.1007","author":[{"given":"Cornelius F.","family":"Waller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,2]]},"reference":[{"key":"1_CR1","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/0014-5793(93)80884-W","volume":"330","author":"M Anafi","year":"1993","unstructured":"Anafi M, Gazit A, Gilon C, Neriah YB, Levitzki A (1993a) Tyrphostin-induced differentiation of mouse erythroleukemia cells. FEBS Lett 330:260\u2013264","journal-title":"FEBS Lett"},{"key":"1_CR2","doi-asserted-by":"crossref","first-page":"3524","DOI":"10.1182\/blood.V82.12.3524.3524","volume":"82","author":"M Anafi","year":"1993","unstructured":"Anafi M, Gazit A, Zehavi A, Ben-Neriah Y, Levitzki A (1993b) Tyrphostin-induced inhibition of p210bcr-abl tyrosine kinase activity induces K562 to differentiate. Blood 82:3524\u20133529","journal-title":"Blood"},{"key":"1_CR3","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/S0037-1963(03)70040-7","volume":"40","author":"M Baccarani","year":"2003","unstructured":"Baccarani M, Russo D, Rosti G, Martinelli G (2003) Interferon-alfa for chronic myeloid leukemia. Semin Hematol 40:22\u201333","journal-title":"Semin Hematol"},{"key":"1_CR4","doi-asserted-by":"publisher","first-page":"4245","DOI":"10.1182\/blood-2004-03-0826","volume":"104","author":"M Baccarani","year":"2004","unstructured":"Baccarani M, Martinelli G, Rosti G, Trabacchi E, Testoni N, Bassi S, Amabile M, Soverini S, Castagnetti F, Cilloni D et al (2004) Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia. Blood 104:4245\u20134251","journal-title":"Blood"},{"key":"1_CR5","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, Cervantes F, Clark RE, Cortes JE, Guilhot F et al (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122:872\u2013884","journal-title":"Blood"},{"key":"1_CR6","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1046\/j.1365-2133.1996.d01-1092.x","volume":"135","author":"RL Barnhill","year":"1996","unstructured":"Barnhill RL, Xiao M, Graves D, Antoniades HN (1996) Expression of platelet-derived growth factor (PDGF)-A, PDGF-B and the PDGF-alpha receptor, but not the PDGF-beta receptor, in human malignant melanoma in vivo. Br J Dermatol 135:898\u2013904","journal-title":"Br J Dermatol"},{"key":"1_CR7","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1200\/JCO.2007.13.4452","volume":"26","author":"CD Blanke","year":"2008","unstructured":"Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS, Raymond AK, Bramwell VH, Baker LH, Maki RG et al (2008) Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 26:626\u2013632","journal-title":"J Clin Oncol"},{"key":"1_CR01","unstructured":"Branford S, Hughes T (2006) Detection of BCR-ABL mutations and resistance to imatinib mesylate. Methods Mol Med 125:93\u2013106"},{"key":"1_CR8","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1073\/pnas.92.7.2558","volume":"92","author":"E Buchdunger","year":"1995","unstructured":"Buchdunger E, Zimmermann J, Mett H, Meyer T, Muller M, Regenass U, Lydon NB (1995) Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class. Proc Natl Acad Sci U S A 92:2558\u20132562","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1_CR9","first-page":"100","volume":"56","author":"E Buchdunger","year":"1996","unstructured":"Buchdunger E, Zimmermann J, Mett H, Meyer T, Muller M, Druker BJ, Lydon NB (1996) Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 56:100\u2013104","journal-title":"Cancer Res"},{"key":"1_CR10","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0022-3565(24)38879-2","volume":"295","author":"E Buchdunger","year":"2000","unstructured":"Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ, Lydon NB (2000) Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 295:139\u2013145","journal-title":"J Pharmacol Exp Ther"},{"key":"1_CR11","first-page":"M11","volume":"1551","author":"E Buchdunger","year":"2001","unstructured":"Buchdunger E, Matter A, Druker BJ (2001) Bcr-Abl inhibition as a modality of CML therapeutics. Biochim Biophys Acta 1551:M11\u2013M18","journal-title":"Biochim Biophys Acta"},{"key":"1_CR12","doi-asserted-by":"crossref","first-page":"3973","DOI":"10.1182\/blood.V93.11.3973","volume":"93","author":"C Carlo-Stella","year":"1999","unstructured":"Carlo-Stella C, Regazzi E, Sammarelli G, Colla S, Garau D, Gazit A, Savoldo B, Cilloni D, Tabilio A, Levitzki A, Rizzoli V (1999) Effects of the tyrosine kinase inhibitor AG957 and an Anti-Fas receptor antibody on CD34(+) chronic myelogenous leukemia progenitor cells. Blood 93:3973\u20133982","journal-title":"Blood"},{"key":"1_CR02","doi-asserted-by":"crossref","unstructured":"Casali PG, Le Cesne A, Poveda Velasco A, et al (2015) Time to definitive failure to the first tyrosine kinase inhibitor in localized GI stromal tumors treated with imatinib as an adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup randomized trial in collaboration with the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas. J Clin Oncol 33:4276\u20134283","DOI":"10.1200\/JCO.2015.62.4304"},{"key":"1_CR13","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1634\/theoncologist.7-5-393","volume":"7","author":"MH Cohen","year":"2002","unstructured":"Cohen MH, Dagher R, Griebel DJ, Ibrahim A, Martin A, Scher NS, Sokol GH, Williams GA, Pazdur R (2002a) US Food and Drug Administration drug approval summaries: imatinib mesylate, mesna tablets, and zoledronic acid. Oncologist 7:393\u2013400","journal-title":"Oncologist"},{"key":"1_CR14","first-page":"935","volume":"8","author":"MH Cohen","year":"2002","unstructured":"Cohen MH, Williams G, Johnson JR, Duan J, Gobburu J, Rahman A, Benson K, Leighton J, Kim SK, Wood R et al (2002b) Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res 8:935\u2013942","journal-title":"Clin Cancer Res"},{"key":"1_CR15","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1158\/1078-0432.12.11.1","volume":"11","author":"MH Cohen","year":"2005","unstructured":"Cohen MH, Johnson JR, Pazdur R (2005) U.S. Food and Drug Administration drug approval summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval. Clin Cancer Res 11:12\u201319","journal-title":"Clin Cancer Res"},{"key":"1_CR16","doi-asserted-by":"crossref","unstructured":"Cohen MH, Farrell A, Justice R, Pazdur R (2009) Approval summary: imatinib mesylate in the treatment of metastatic and\/or unresectable malignant gastrointestinal stromal tumors. Oncologist","DOI":"10.1634\/theoncologist.2008-0255"},{"key":"1_CR17","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1200\/JCO.2013.51.2046","volume":"32","author":"CL Corless","year":"2014","unstructured":"Corless CL, Ballman KV, Antonescu CR et al (2014) Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z900 trial. J Clin Oncol 32:1563\u20131570","journal-title":"J Clin Oncol"},{"key":"1_CR18","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1182\/blood-2003-01-0025","volume":"102","author":"J Cortes","year":"2003","unstructured":"Cortes J, Giles F, O\u2019Brien S, Thomas D, Garcia-Manero G, Rios MB, Faderl S, Verstovsek S, Ferrajoli A, Freireich EJ et al (2003) Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha. Blood 102:83\u201386","journal-title":"Blood"},{"key":"1_CR19","first-page":"3034","volume":"8","author":"R Dagher","year":"2002","unstructured":"Dagher R, Cohen M, Williams G, Rothmann M, Gobburu J, Robbie G, Rahman A, Chen G, Staten A, Griebel D, Pazdur R (2002) Approval summary: imatinib mesylate in the treatment of metastatic and\/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res 8:3034\u20133038","journal-title":"Clin Cancer Res"},{"key":"1_CR20","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1126\/science.2406902","volume":"247","author":"GQ Daley","year":"1990","unstructured":"Daley GQ, Van Etten RA, Baltimore D (1990) Induction of chronic myelogenous leukemia in mice by the P210bcr\/abl gene of the Philadelphia chromosome. Science 247:824\u2013830","journal-title":"Science"},{"key":"1_CR21","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1097\/00062752-199807000-00010","volume":"5","author":"MW Deininger","year":"1998","unstructured":"Deininger MW, Goldman JM (1998) Chronic myeloid leukemia. Curr Opin Hematol 5:302\u2013308","journal-title":"Curr Opin Hematol"},{"key":"1_CR22","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.1182\/blood.V90.9.3691","volume":"90","author":"MW Deininger","year":"1997","unstructured":"Deininger MW, Goldman JM, Lydon N, Melo JV (1997) The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood 90:3691\u20133698","journal-title":"Blood"},{"key":"1_CR23","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","volume":"96","author":"MW Deininger","year":"2000","unstructured":"Deininger MW, Goldman JM, Melo JV (2000) The molecular biology of chronic myeloid leukemia. Blood 96:3343\u20133356","journal-title":"Blood"},{"key":"1_CR24","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1182\/blood-2004-08-3097","volume":"105","author":"M Deininger","year":"2005","unstructured":"Deininger M, Buchdunger E, Druker BJ (2005) The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105:2640\u20132653","journal-title":"Blood"},{"issue":"Suppl 5","key":"1_CR25","doi-asserted-by":"publisher","first-page":"S52","DOI":"10.1016\/S0959-8049(02)80603-7","volume":"38","author":"GD Demetri","year":"2002","unstructured":"Demetri GD (2002) Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571). Eur J Cancer 38(Suppl 5):S52\u2013S59","journal-title":"Eur J Cancer"},{"key":"1_CR26","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1056\/NEJMoa020461","volume":"347","author":"GD Demetri","year":"2002","unstructured":"Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M et al (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472\u2013480","journal-title":"N Engl J Med"},{"key":"1_CR27","doi-asserted-by":"publisher","first-page":"4808","DOI":"10.1182\/blood-2008-07-077958","volume":"112","author":"BJ Druker","year":"2008","unstructured":"Druker BJ (2008) Translation of the Philadelphia chromosome into therapy for CML. Blood 112:4808\u20134817","journal-title":"Blood"},{"key":"1_CR28","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1172\/JCI9083","volume":"105","author":"BJ Druker","year":"2000","unstructured":"Druker BJ, Lydon NB (2000) Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 105:3\u20137","journal-title":"J Clin Invest"},{"key":"1_CR29","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nm0596-561","volume":"2","author":"BJ Druker","year":"1996","unstructured":"Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of BCR-ABL positive cells. Nat Med 2:561\u2013566","journal-title":"Nat Med"},{"key":"1_CR30","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","volume":"344","author":"BJ Druker","year":"2001","unstructured":"Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R, Talpaz M (2001a) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344:1038\u20131042","journal-title":"N Engl J Med"},{"key":"1_CR31","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","volume":"344","author":"BJ Druker","year":"2001","unstructured":"Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL (2001b) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031\u20131037","journal-title":"N Engl J Med"},{"key":"1_CR32","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O\u2019Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MW, Silver RT, Goldman JM, Stone RM et al (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355:2408\u20132417","journal-title":"N Engl J Med"},{"issue":"3","key":"1_CR33","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1200\/JCO.2016.68.2914","volume":"35","author":"G Etienne","year":"2017","unstructured":"Etienne G, Guilhot J, Rea D, Rigal-Huguet F, Nicolini F, Charbonnier A, Guerci-Bresler A, Legros L, Varet B, Gardembas M, Dubruille V, Tulliez M, Noel MP, Ianotto JC, Villemagne B, Carr\u00e9 M, Guilhot F, Rousselot P, Mahon FX (2017) Long-term follow-up of the french stop imatinib (STIM1) study in patients with chronic myeloid leukemia. J Clin Oncol 35(3):298\u2013305. https:\/\/doi.org\/10.1200\/JCO.2016.68.2914 Epub 2016 Oct 31","journal-title":"J Clin Oncol"},{"key":"1_CR34","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1006\/bcmd.1997.0155","volume":"23","author":"C Gambacorti-Passerini","year":"1997","unstructured":"Gambacorti-Passerini C, Le Coutre P, Mologni L, Fanelli M, Bertazolli C, Marchesi E, Di Nicola M, Biondi A, Corneo GM, Belotti D et al (1997) Inhibition of the ABL kinase activity blocks the proliferation of BCR\/ABL\u2009+\u2009leukemic cells and induces apoptosis. Blood Cells Mol Dis 23:380\u2013394","journal-title":"Blood Cells Mol Dis"},{"key":"1_CR35","doi-asserted-by":"publisher","first-page":"4298","DOI":"10.1182\/blood-2003-04-1010","volume":"102","author":"M Gardembas","year":"2003","unstructured":"Gardembas M, Rousselot P, Tulliez M, Vigier M, Buzyn A, Rigal-Huguet F, Legros L, Michallet M, Berthou C, Cheron N et al (2003) Results of a prospective phase 2 study combining imatinib mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukemia in chronic phase. Blood 102:4298\u20134305","journal-title":"Blood"},{"key":"1_CR36","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1126\/science.1062538","volume":"293","author":"ME Gorre","year":"2001","unstructured":"Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293:876\u2013880","journal-title":"Science"},{"key":"1_CR37","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/S0140-6736(98)03030-X","volume":"352","author":"A Gratwohl","year":"1998","unstructured":"Gratwohl A, Hermans J, Goldman JM, Arcese W, Carreras E, Devergie A, Frassoni F, Gahrton G, Kolb HJ, Niederwieser D et al (1998) Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic leukemia working party of the European group for blood and marrow transplantation. Lancet 352:1087\u20131092","journal-title":"Lancet"},{"key":"1_CR38","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1002\/ijc.1190","volume":"92","author":"A Greco","year":"2001","unstructured":"Greco A, Roccato E, Miranda C, Cleris L, Formelli F, Pierotti MA (2001) Growth-inhibitory effect of STI571 on cells transformed by the COL1A1\/PDGFB rearrangement. Int J Cancer 92:354\u2013360","journal-title":"Int J Cancer"},{"key":"1_CR39","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1634\/theoncologist.9-3-271","volume":"9","author":"F Guilhot","year":"2004","unstructured":"Guilhot F (2004) Indications for imatinib mesylate therapy and clinical management. Oncologist 9:271\u2013281","journal-title":"Oncologist"},{"key":"1_CR40","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1200\/JCO.2003.12.154","volume":"21","author":"EA Hahn","year":"2003","unstructured":"Hahn EA, Glendenning GA, Sorensen MV, Hudgens SA, Druker BJ, Guilhot F, Larson RA, O\u2019Brien SG, Dobrez DG, Hensley ML, Cella D (2003) Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study. J Clin Oncol 21:2138\u20132146","journal-title":"J Clin Oncol"},{"key":"1_CR41","doi-asserted-by":"crossref","unstructured":"Hatfield A, Owen S, Pilot PR (2007) In reply to \u2018Cardiotoxicity of the cancer therapeutic agent imatinib mesylate\u2019. Nat Med 13, 13: author reply 15\u201316","DOI":"10.1038\/nm0107-13a"},{"key":"1_CR42","doi-asserted-by":"publisher","first-page":"4686","DOI":"10.1182\/blood-2006-11-055186","volume":"109","author":"R Hehlmann","year":"2007","unstructured":"Hehlmann R, Berger U, Pfirrmann M, Heimpel H, Hochhaus A, Hasford J, Kolb HJ, Lahaye T, Maywald O, Reiter A et al (2007a) Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia. Blood 109:4686\u20134692","journal-title":"Blood"},{"key":"1_CR43","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/S0140-6736(07)61165-9","volume":"370","author":"R Hehlmann","year":"2007","unstructured":"Hehlmann R, Hochhaus A, Baccarani M (2007b) Chronic myeloid leukaemia. Lancet 370:342\u2013350","journal-title":"Lancet"},{"key":"1_CR44","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1200\/JCO.2010.32.0598","volume":"29","author":"R Hehlmann","year":"2011","unstructured":"Hehlmann R, Lauseker M, Jung-Munkwitz S, Leitner A, Muller MC, Pletsch N, Proetel U, Haferlach C, Schlegelberger B, Balleisen L et al (2011) Tolerability-adapted imatinib 800\u00a0mg\/d versus 400\u00a0mg\/d versus 400\u00a0mg\/d plus interferon-alpha in newly diagnosed chronic myeloid leukemia. J Clin Oncol 29:1634\u20131642","journal-title":"J Clin Oncol"},{"issue":"11","key":"1_CR45","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1038\/leu.2017.253","volume":"31","author":"R Hehlmann","year":"2017","unstructured":"Hehlmann R, Lauseker M, Sau\u00dfele S, Pfirrmann M, Krause S, Kolb HJ, Neubauer A, Hossfeld DK, Nerl C, Gratwohl A, Baerlocher GM, Heim D, Br\u00fcmmendorf TH, Fabarius A, Haferlach C, Schlegelberger B, M\u00fcller MC, Jeromin S, Proetel U, Kohlbrenner K, Voskanyan A, Rinaldetti S, Seifarth W, Spie\u00df B, Balleisen L, Goebeler MC, H\u00e4nel M, Ho A, Dengler J, Falge C, Kanz L, Kremers S, Burchert A, Kneba M, Stegelmann F, K\u00f6hne CA, Lindemann HW, Waller CF, Pfreundschuh M, Spiekermann K, Berdel WE, M\u00fcller L, Edinger M, Mayer J, Beelen DW, Bentz M, Link H, Hertenstein B, Fuchs R, Wernli M, Schlegel F, Schlag R, de Wit M, Tr\u00fcmper L, Hebart H, Hahn M, Thomalla J, Scheid C, Schafhausen P, Verbeek W, Eckart MJ, Gassmann W, Pezzutto A, Schenk M, Brossart P, Geer T, Bildat S, Sch\u00e4fer E, Hochhaus A, Hasford J (2017) Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. Leukemia 31(11):2398\u20132406. https:\/\/doi.org\/10.1038\/leu.2017.253 Epub 2017 Aug 14","journal-title":"Leukemia"},{"key":"1_CR46","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1200\/JCO.2002.20.6.1692","volume":"20","author":"MC Heinrich","year":"2002","unstructured":"Heinrich MC, Blanke CD, Druker BJ, Corless CL (2002a) Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 20:1692\u20131703","journal-title":"J Clin Oncol"},{"key":"1_CR47","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1053\/hupa.2002.124124","volume":"33","author":"MC Heinrich","year":"2002","unstructured":"Heinrich MC, Rubin BP, Longley BJ, Fletcher JA (2002b) Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. Hum Pathol 33:484\u2013495","journal-title":"Hum Pathol"},{"key":"1_CR48","doi-asserted-by":"publisher","first-page":"4342","DOI":"10.1200\/JCO.2003.04.190","volume":"21","author":"MC Heinrich","year":"2003","unstructured":"Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, McGreevey LS, Chen CJ, Van den Abbeele AD, Druker BJ et al (2003a) Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21:4342\u20134349","journal-title":"J Clin Oncol"},{"key":"1_CR49","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1126\/science.1079666","volume":"299","author":"MC Heinrich","year":"2003","unstructured":"Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, Singer S, Griffith DJ, Haley A, Town A et al (2003b) PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299:708\u2013710","journal-title":"Science"},{"key":"1_CR50","doi-asserted-by":"publisher","first-page":"5360","DOI":"10.1200\/JCO.2008.17.4284","volume":"26","author":"MC Heinrich","year":"2008","unstructured":"Heinrich MC, Owzar K, Corless CL, Hollis D, Borden EC, Fletcher CD, Ryan CW, von Mehren M, Blanke CD, Rankin C et al (2008) Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol 26:5360\u20135367","journal-title":"J Clin Oncol"},{"key":"1_CR51","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/344251a0","volume":"344","author":"N Heisterkamp","year":"1990","unstructured":"Heisterkamp N, Jenster G, ten Hoeve J, Zovich D, Pattengale PK, Groffen J (1990) Acute leukaemia in BCR\/ABL transgenic mice. Nature 344:251\u2013253","journal-title":"Nature"},{"key":"1_CR52","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1182\/blood-2007-07-103523","volume":"111","author":"A Hochhaus","year":"2008","unstructured":"Hochhaus A, Druker B, Sawyers C, Guilhot F, Schiffer CA, Cortes J, Niederwieser DW, Gambacorti-Passerini C, Stone RM, Goldman J et al (2008) Favorable long-term follow-up results over 6\u00a0years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment. Blood 111:1039\u20131043","journal-title":"Blood"},{"key":"1_CR53","doi-asserted-by":"publisher","first-page":"250","DOI":"10.4161\/cc.10.2.14537","volume":"10","author":"A Hochhaus","year":"2011","unstructured":"Hochhaus A, La Rosee P, Muller MC, Ernst T, Cross NC (2011) Impact of BCR-ABL mutations on patients with chronic myeloid leukemia. Cell Cycle 10:250\u2013260","journal-title":"Cell Cycle"},{"issue":"10","key":"1_CR54","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1609324","volume":"376","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, Baccarani M, Deininger MW, Cervantes F, Fujihara S, Ortmann CE, Menssen HD, Kantarjian H, O\u2019Brien SG, Druker BJ, Investigators IRIS (2017) Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med 376(10):917\u2013927. https:\/\/doi.org\/10.1056\/NEJMoa1609324","journal-title":"N Engl J Med"},{"issue":"10","key":"1_CR55","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1161\/CIRCULATIONAHA.112.000765","volume":"127","author":"MM Hoeper","year":"2013","unstructured":"Hoeper MM, Barst RJ, Bourge RC, Feldman J, Ghofrani HA, Gali\u00e9 N, G\u00f3mez-S\u00e1nchez MA, Grimminger F, Gr\u00fcnig E, Hassoun PM et al (2013) Imatinib mesylate as add-on therapy for pulmonary arterial hypertension results of the randomized IMPRES study. Circulation 127(10):1128\u20131138","journal-title":"Circulation"},{"key":"1_CR56","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1056\/NEJMoa030513","volume":"349","author":"TP Hughes","year":"2003","unstructured":"Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML, Gathmann I, Bolton AE, van Hoomissen IC, Goldman JM, Radich JP (2003) Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 349:1423\u20131432","journal-title":"N Engl J Med"},{"key":"1_CR57","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1001\/jama.2012.347","volume":"307","author":"H Joensuu","year":"2012","unstructured":"Joensuu H, Eriksson M, Sundby Hall K, Hartmann JT, Pink D, Schutte J, Ramadori G, Hohenberger P, Duyster J, Al-Batran SE et al (2012) One versus three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA 307:1265\u20131272","journal-title":"JAMA"},{"key":"1_CR58","doi-asserted-by":"publisher","first-page":"4635","DOI":"10.1182\/blood-2006-10-050054","volume":"109","author":"JV Jovanovic","year":"2007","unstructured":"Jovanovic JV, Score J, Waghorn K, Cilloni D, Gottardi E, Metzgeroth G, Erben P, Popp H, Walz C, Hochhaus A et al (2007) Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Blood 109:4635\u20134640","journal-title":"Blood"},{"key":"1_CR59","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1056\/NEJMoa011573","volume":"346","author":"H Kantarjian","year":"2002","unstructured":"Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, Niederwieser D, Resta D, Capdeville R, Zoellner U et al (2002a) Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346:645\u2013652","journal-title":"N Engl J Med"},{"key":"1_CR60","first-page":"2167","volume":"8","author":"HM Kantarjian","year":"2002","unstructured":"Kantarjian HM, O\u2019Brien S, Cortes JE, Smith TL, Rios MB, Shan J, Yang Y, Giles FJ, Thomas DA, Faderl S et al (2002b) Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate. Clin Cancer Res 8:2167\u20132176","journal-title":"Clin Cancer Res"},{"key":"1_CR61","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/nm1446","volume":"12","author":"R Kerkela","year":"2006","unstructured":"Kerkela R, Grazette L, Yacobi R, Iliescu C, Patten R, Beahm C, Walters B, Shevtsov S, Pesant S, Clubb FJ et al (2006) Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 12:908\u2013916","journal-title":"Nat Med"},{"key":"1_CR62","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/0092-8674(84)90438-0","volume":"37","author":"JB Konopka","year":"1984","unstructured":"Konopka JB, Watanabe SM, Witte ON (1984) An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity. Cell 37:1035\u20131042","journal-title":"Cell"},{"key":"1_CR63","doi-asserted-by":"publisher","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","volume":"111","author":"RA Larsen","year":"2008","unstructured":"Larsen RA, Druker BJ, Guilhot F, O\u2019Brien SG, Riviere GJ, Krahnke T, Gathmann I, Wang Y et al (2008) Imatinib pharmacokinetics and its correlation with response and safety in chronic phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 111:4022\u20134028","journal-title":"Blood"},{"key":"1_CR64","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1093\/jnci\/91.2.163","volume":"92","author":"P Coutre Le","year":"1999","unstructured":"Le Coutre P, Mologni L, Cleris L, Marchesi E, Buchdunger E, Giardini R, Formelli F, Gambacorti-Passerini C (1999) In vivo eradication of human BCR\/ABL-positive leukemia cells with an ABL kinase inhibitor. J Natl Cancer Inst 92:163\u2013168","journal-title":"J Natl Cancer Inst"},{"key":"1_CR65","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1126\/science.7892601","volume":"267","author":"A Levitzky","year":"1995","unstructured":"Levitzky A, Gazit A (1995) Tyrosine kinase inhibition: an approach to drug development. Science 267:1782\u20131788","journal-title":"Science"},{"key":"1_CR66","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1126\/science.2408149","volume":"247","author":"TG Lugo","year":"1990","unstructured":"Lugo TG, Pendergast AM, Muller AJ, Witte ON (1990) Tyrosine kinase activity and transformation potency of BCR-ABL oncogene products. Science 247:1079\u20131082","journal-title":"Science"},{"key":"1_CR67","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/S0002-9440(10)64946-2","volume":"156","author":"ML Lux","year":"2000","unstructured":"Lux ML, Rubin BP, Biase TL, Chen CJ, Maclure T, Demetri GD, Xiao S, Singer S, Fletcher CD, Fletcher JA (2000) Kit extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am J Pathol 156:791\u2013795","journal-title":"Am J Pathol"},{"key":"1_CR68","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.2165\/00003495-200161120-00007","volume":"61","author":"K Lyseng-Williamson","year":"2001","unstructured":"Lyseng-Williamson K, Jarvis B (2001) Imatinib. Drugs 61:1765\u20131774","journal-title":"Drugs"},{"key":"1_CR69","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","volume":"11","author":"FX Mahon","year":"2010","unstructured":"Mahon FX, Rea D, Guilhot J, Guilhot F, Huguet F, Nicolini F, Legros L, Charbonnier A, Guerci A, Varet B et al (2010) Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2\u00a0years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 11:1029\u20131035","journal-title":"Lancet Oncol"},{"key":"1_CR70","doi-asserted-by":"crossref","unstructured":"Mahon FX, Richter J, Guilhot J, Hjorth-Hansen H, Almeida A, Janssen JWM, Mayer J, Porkka K, Panayiotidis P, Stromberg U, Berger MG, Diamond J, Ehrencrona H, Kairisto V, Machova Polakova K, Mueller MC, Mustjoki S, Hochhaus A, Pfirrmann M, Saussele S (2016) Cessation of tyrosine kinase inhibitors treatment in chronic myeloid leukemia patients with deep molecular response: results of the Euro-Ski trial. Blood, 128, abstract 787","DOI":"10.1007\/978-3-319-33198-0_13"},{"key":"1_CR71","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s00280-008-0764-0","volume":"63","author":"E Marangon","year":"2009","unstructured":"Marangon E, Citterio M, Sala F, Barisone E, Lippi AA, Rizzari C, Biondi A, D\u2019Incalci M, Zucchetti M (2009) Pharmacokinetic profile of imatinib mesylate and N-demethyl-imatinib (CGP74588) in children with newly diagnosed Ph\u2009+\u2009acute leukemias. Cancer Chemother Pharmacol 63:563\u2013566","journal-title":"Cancer Chemother Pharmacol"},{"key":"1_CR72","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1200\/JCO.2002.20.1.325","volume":"20","author":"MJ Mauro","year":"2002","unstructured":"Mauro MJ, O\u2019Dwyer M, Heinrich MC, Druker BJ (2002) STI571: a paradigm of new agents for cancer therapeutics. J Clin Oncol 20:325\u2013334","journal-title":"J Clin Oncol"},{"key":"1_CR73","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2147\/JEP.S26894","volume":"5","author":"P Moinzadeh","year":"2013","unstructured":"Moinzadeh P, Hunzelmann N, Krieg T (2013) Pharmacology and rationale for imatinib in the treatment of scleroderma. J Exp Pharmacol 5:15\u201322","journal-title":"J Exp Pharmacol"},{"key":"1_CR74","doi-asserted-by":"publisher","first-page":"120","DOI":"10.2174\/138161209787002933","volume":"15","author":"BA Mueller","year":"2009","unstructured":"Mueller BA (2009) Imatinib and its successors: how modern chemistry has changed drug development. Curr Pharm Design 15:120\u2013133","journal-title":"Curr Pharm Design"},{"key":"1_CR75","unstructured":"NCCN Practice Guidelines in Oncology, v. 3 (2018). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cml.pdf"},{"key":"1_CR76","unstructured":"NCCN_Practice_Guidelines_in_Oncology, v. 1 (2018). https:\/\/www.nccn.org\/professionals\/physician_gls\/#site"},{"key":"1_CR77","first-page":"1497","volume":"132","author":"PC Nowell","year":"1960","unstructured":"Nowell PC, Hungerford DA (1960) A minute chromosome in human chronic granulocytic leukemia. Science 132:1497","journal-title":"Science"},{"key":"1_CR78","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1182\/blood.V112.11.76.76","volume":"112","author":"SG O\u2019Brien","year":"2008","unstructured":"O\u2019Brien SG, Guilhot F, Goldman J, Hochhaus A, Hughes T, Radich J, Rudoltz M, Filian J, Gathmann I, Druker B et al (2008) International randomized study of interferon versus STI571 (IRIS) 7-year follow-up: sustained survival, low rate of transformation and increased rate of major molecular response (MMR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib (IM). Blood 112:76","journal-title":"Blood"},{"key":"1_CR79","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1002\/cncr.11620","volume":"98","author":"S O\u2019Brien","year":"2003","unstructured":"O\u2019Brien S, Giles F, Talpaz M, Cortes J, Rios MB, Shan J, Thomas D, Andreeff M, Kornblau S, Faderl S et al (2003a) Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase. Cancer 98:888\u2013893","journal-title":"Cancer"},{"key":"1_CR80","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1056\/NEJMoa022457","volume":"348","author":"SG O\u2019Brien","year":"2003","unstructured":"O\u2019Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T et al (2003b) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348:994\u20131004","journal-title":"N Engl J Med"},{"key":"1_CR81","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.rmed.2017.08.032","volume":"131","author":"A Ogawa","year":"2017","unstructured":"Ogawa A, Miyaji K, Matsubara H (2017) Efficacy and safety of long-term imatinib therapy for patients with pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis. Respir Med 131:215\u2013219. https:\/\/doi.org\/10.1016\/j.rmed.2017.08.032 Epub 2017 Sep 12","journal-title":"Respir Med"},{"key":"1_CR82","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.1182\/blood.V97.8.2440","volume":"97","author":"K Okuda","year":"2001","unstructured":"Okuda K, Weisberg E, Gilliland DG, Griffin JD (2001) ARG tyrosine kinase activity is inhibited by STI571. Blood 97:2440\u20132448","journal-title":"Blood"},{"key":"1_CR83","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1182\/blood-2001-12-0181","volume":"100","author":"OG Ottmann","year":"2002","unstructured":"Ottmann OG, Druker BJ, Sawyers CL, Goldman JM, Reiffers J, Silver RT, Tura S, Fischer T, Deininger MW, Schiffer CA et al (2002) A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 100:1965\u20131971","journal-title":"Blood"},{"key":"1_CR84","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1182\/blood-2004-01-0246","volume":"104","author":"A Pardanani","year":"2004","unstructured":"Pardanani A, Tefferi A (2004) Imatinib targets other than BCR\/ABL and their clinical relevance in myeloid disorders. Blood 104:1931\u20131939","journal-title":"Blood"},{"key":"1_CR85","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1056\/NEJMoa1004095","volume":"363","author":"C Preudhomme","year":"2010","unstructured":"Preudhomme C, Guilhot J, Nicolini FE, Guerci-Bresler A, Rigal-Huguet F, Maloisel F, Coiteux V, Gardembas M, Berthou C, Vekhoff A et al (2010) Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N Engl J Med 363:2511\u20132521","journal-title":"N Engl J Med"},{"key":"1_CR86","doi-asserted-by":"publisher","unstructured":"Rea D, Nicolini FE, Tulliez M, Guilhot F, Guilhot J, Guerci-Bresler A, Gardembas M, Coiteux V, Guillerm G, Legros L, Etienne G, Pignon JM, Villemagne B, Escoffre-Barbe M, Ianotto JC, Charbonnier A, Johnson-Ansah H, Noel MP, Rousselot P, Mahon FX; France Intergroupe des Leuc\u00e9mies My\u00e9lo\u00efdes Chroniques (2017) Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study. Blood. 16;129(7):846\u2013854. https:\/\/doi.org\/10.1182\/blood-2016-09-742205 Epub 2016 Dec 8","DOI":"10.1182\/blood-2016-09-742205"},{"issue":"1","key":"1_CR87","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/bjh.14973","volume":"180","author":"D Rea","year":"2018","unstructured":"Rea D, Mahon FX (2018) How I manage relapse of chronic myeloid leukaemia after stopping tyrosine kinase inhibitor therapy. Br J Haematol 180(1):24\u201332. https:\/\/doi.org\/10.1111\/bjh.14973 Epub 2017 Oct 19","journal-title":"Br J Haematol"},{"key":"1_CR88","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/243290a0","volume":"243","author":"JD Rowley","year":"1973","unstructured":"Rowley JD (1973) A new consistent abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243:290\u2013293","journal-title":"Nature"},{"key":"1_CR89","doi-asserted-by":"crossref","unstructured":"Sau\u00dfele S, Krauss MP, Hehlmann R, Lauseker M, Proetel U, Kalmanti L, Hanfstein B, Fabarius A, Kraemer D, Berdel WE, Bentz M, Staib P, de Wit M, Wernli M, Zettl F, Hebart HF, Hahn M, Heymanns J, Schmidt-Wolf I, Schmitz N, Eckart MJ, Gassmann W, Bartholom\u20acaus A, Pezzutto A, Leibundgut EO, Heim D, Krause SW, Burchert A, Hofmann WK, Hasford J, Hochhaus A, Pfirrmann M, M\u20aculler MC Schweizerische Arbeitsgemeinschaft fur Klinische Krebsforschung and the German CML Study Group (2015) Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV. Blood 126:42\u201349","DOI":"10.1182\/blood-2015-01-617993"},{"issue":"8","key":"1_CR90","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1038\/leu.2016.115","volume":"30","author":"S Sau\u00dfele","year":"2016","unstructured":"Sau\u00dfele S, Richter J, Hochhaus A, Hochhaus A, Mahon FX (2016) The concept of treatment-free remission in chronic myeloid leukemia. Leukemia 30(8):1638\u20131647. https:\/\/doi.org\/10.1038\/leu.2016.115 Epub 2016 May 2","journal-title":"Leukemia"},{"key":"1_CR91","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","volume":"340","author":"CL Sawyers","year":"1999","unstructured":"Sawyers CL (1999) Chronic myeloid leukemia. N Engl J Med 340:1330\u20131340","journal-title":"N Engl J Med"},{"key":"1_CR92","doi-asserted-by":"publisher","first-page":"3530","DOI":"10.1182\/blood.V99.10.3530","volume":"99","author":"CL Sawyers","year":"2002","unstructured":"Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG, Schiffer CA, Talpaz M, Guilhot F, Deininger MW et al (2002) Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 99:3530\u20133539","journal-title":"Blood"},{"key":"1_CR93","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1056\/NEJMct071828","volume":"357","author":"CA Schiffer","year":"2007","unstructured":"Schiffer CA (2007) BCR-ABL tyrosine kinase inhibitors in chronic myelogenous leukemia. N Engl J Med 357:258\u2013265","journal-title":"N Engl J Med"},{"key":"1_CR94","doi-asserted-by":"publisher","first-page":"7389","DOI":"10.1038\/sj.onc.1206942","volume":"22","author":"NP Shah","year":"2003","unstructured":"Shah NP, Sawyers CL (2003) Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias. Oncogene 22:7389\u20137395","journal-title":"Oncogene"},{"key":"1_CR95","doi-asserted-by":"publisher","first-page":"3204","DOI":"10.1200\/JCO.2007.14.9260","volume":"26","author":"NP Shah","year":"2008","unstructured":"Shah NP, Kantarjian HM, Kim DW, Rea D, Dorlhiac-Llacer PE, Milone JH, Vela-Ojeda J, Silver RT, Khoury HJ, Charbonnier A et al (2008) Intermittent target inhibition with dasatinib 100\u00a0mg once daily preserves efficacy and improves tolerability in imatinib-resistant and intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 26:3204\u20133212","journal-title":"J Clin Oncol"},{"key":"1_CR96","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1182\/blood.V99.6.1928","volume":"99","author":"M Talpaz","year":"2002","unstructured":"Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot F, Schiffer CA, Fischer T, Deininger MW, Lennard AL et al (2002) Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 99:1928\u20131937","journal-title":"Blood"},{"key":"1_CR97","doi-asserted-by":"crossref","unstructured":"Verweij J, Casali PG, Zalcberg J, et al. (2004) Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: Randomised trial. Lancet 364:1127\u20131134","DOI":"10.1016\/S0140-6736(04)17098-0"},{"key":"1_CR98","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1038\/sj.leu.2402889","volume":"17","author":"N Bubnoff von","year":"2003","unstructured":"von Bubnoff N, Peschel C, Duyster J (2003) Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back. Leukemia 17:829\u2013838","journal-title":"Leukemia"},{"key":"1_CR99","doi-asserted-by":"publisher","unstructured":"von Mehren M, Joensuu H. (2018) Gastrointestinal Stromal Tumors. J Clin Oncol. 10; 36(2):136\u2013143. https:\/\/doi.org\/10.1200\/jco.2017.74.9705 Epub 2017 Dec 8","DOI":"10.1200\/jco.2017.74.9705"},{"key":"1_CR100","doi-asserted-by":"crossref","unstructured":"van Oosterom AT, Judson I, Verweij J, et al. (2001) Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: A phase I study. Lancet 358:1421\u20131423","DOI":"10.1016\/S0140-6736(01)06535-7"},{"key":"1_CR101","doi-asserted-by":"crossref","first-page":"4603","DOI":"10.1182\/blood.V86.12.4603.bloodjournal86124603","volume":"86","author":"JW Voncken","year":"1995","unstructured":"Voncken JW, Kaartinen V, Pattengale PK, Germeraad WT, Groffen J, Heisterkamp N (1995) BCR\/ABL P210 and P190 cause distinct leukemia in transgenic mice. Blood 86:4603\u20134611","journal-title":"Blood"}],"container-title":["Recent Results in Cancer Research","Small Molecules in Hematology"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-319-91439-8_1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,6]],"date-time":"2025-07-06T04:52:33Z","timestamp":1751777553000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-3-319-91439-8_1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"ISBN":["9783319914381","9783319914398"],"references-count":103,"URL":"https:\/\/doi.org\/10.1007\/978-3-319-91439-8_1","relation":{},"ISSN":["0080-0015","2197-6767"],"issn-type":[{"value":"0080-0015","type":"print"},{"value":"2197-6767","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018]]}}}